Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Novel techniques in the development of osteoporosis drug therapy: the osteoclast ruffled-border vacuolar H(+)-ATPase as an emerging target.

Kartner N, Manolson MF.

Expert Opin Drug Discov. 2014 May;9(5):505-22. doi: 10.1517/17460441.2014.902155. Review.

PMID:
24749538
2.

5-(5,6-Dichloro-2-indolyl)-2-methoxy-2,4-pentadienamides: novel and selective inhibitors of the vacuolar H+-ATPase of osteoclasts with bone antiresorptive activity.

Gagliardi S, Nadler G, Consolandi E, Parini C, Morvan M, Legave MN, Belfiore P, Zocchetti A, Clarke GD, James I, Nambi P, Gowen M, Farina C.

J Med Chem. 1998 May 7;41(10):1568-73.

PMID:
9572882
3.

The vacuolar ATPase in bone cells: a potential therapeutic target in osteoporosis.

Yuan FL, Li X, Lu WG, Li CW, Li JP, Wang Y.

Mol Biol Rep. 2010 Oct;37(7):3561-6. doi: 10.1007/s11033-010-0004-7. Epub 2010 Feb 25. Review.

PMID:
20182803
4.

V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption.

Qin A, Cheng TS, Pavlos NJ, Lin Z, Dai KR, Zheng MH.

Int J Biochem Cell Biol. 2012 Sep;44(9):1422-35. doi: 10.1016/j.biocel.2012.05.014. Epub 2012 May 29. Review.

PMID:
22652318
5.

Novel bone antiresorptive agents that selectively inhibit the osteoclast V-H+-ATPase.

Farina C, Gagliardi S, Nadler G, Morvan M, Parini C, Belfiore P, Visentin L, Gowen M.

Farmaco. 2001 Jan-Feb;56(1-2):113-6. Review.

PMID:
11347950
6.

The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase.

David P, Nguyen H, Barbier A, Baron R.

J Bone Miner Res. 1996 Oct;11(10):1498-507.

PMID:
8889850
7.

Selective inhibition of osteoclast vacuolar H(+)-ATPase.

Farina C, Gagliardi S.

Curr Pharm Des. 2002;8(23):2033-48. Review.

PMID:
12171517
8.
9.

Characterization and cellular distribution of the osteoclast ruffled membrane vacuolar H+-ATPase B-subunit using isoform-specific antibodies.

Mattsson JP, Skyman C, Palokangas H, Väänänen KH, Keeling DJ.

J Bone Miner Res. 1997 May;12(5):753-60.

10.

Inhibition of osteoclast bone resorption by disrupting vacuolar H+-ATPase a3-B2 subunit interaction.

Kartner N, Yao Y, Li K, Crasto GJ, Datti A, Manolson MF.

J Biol Chem. 2010 Nov 26;285(48):37476-90. doi: 10.1074/jbc.M110.123281. Epub 2010 Sep 13.

11.

Disruption of the V-ATPase functionality as a way to uncouple bone formation and resorption - a novel target for treatment of osteoporosis.

Thudium CS, Jensen VK, Karsdal MA, Henriksen K.

Curr Protein Pept Sci. 2012 Mar;13(2):141-51. Review.

PMID:
22044152
12.
13.
14.

Future developments in osteoporosis therapy.

Ng KW.

Endocr Metab Immune Disord Drug Targets. 2009 Dec;9(4):371-84.

PMID:
19857200
15.

Structure and function of V-ATPases in osteoclasts: potential therapeutic targets for the treatment of osteolysis.

Xu J, Cheng T, Feng HT, Pavlos NJ, Zheng MH.

Histol Histopathol. 2007 Apr;22(4):443-54. Review.

PMID:
17290355
16.

A selective inhibitor of the osteoclastic V-H(+)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats.

Visentin L, Dodds RA, Valente M, Misiano P, Bradbeer JN, Oneta S, Liang X, Gowen M, Farina C.

J Clin Invest. 2000 Jul;106(2):309-18.

17.

Expression of vacuolar H(+)-ATPase in mouse osteoclasts during in vitro differentiation.

Wang ZQ, Hemken P, Menton D, Gluck S.

Am J Physiol. 1992 Aug;263(2 Pt 2):F277-83.

PMID:
1387291
18.

Therapeutic targeting of osteoclast function and pathways.

Broadhead ML, Clark JC, Dass CR, Choong PF, Myers DE.

Expert Opin Ther Targets. 2011 Feb;15(2):169-81. doi: 10.1517/14728222.2011.546351. Epub 2011 Jan 5. Review.

PMID:
21204734
20.

Appropriate models for novel osteoporosis drug discovery and future perspectives.

Gennari L, Rotatori S, Bianciardi S, Gonnelli S, Nuti R, Merlotti D.

Expert Opin Drug Discov. 2015;10(11):1201-16. doi: 10.1517/17460441.2015.1080685. Epub 2015 Aug 19.

PMID:
26292627
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk